PremiumCompany AnnouncementsStructure Therapeutics Advances in Obesity Treatment Pipeline Structure Therapeutics, Inc.: Promising Outlook with Aleniglipron in Obesity Treatment and Strategic Advancements Justify Buy Rating Structure Therapeutics price target lowered to $87 from $91 at Citizens JMP PremiumThe FlyStructure Therapeutics initiated with a Buy at Stifel Short Report: CompoSecure shorts at multi-month lows Structure’s obesity pipeline value prop ‘unperturbed,’ says H.C. Wainwright PremiumCompany AnnouncementsStructure Therapeutics Reports Strong Q3 2024 Results Structure Therapeutics expects cash to fund operations through at least 2027 Structure Therapeutics doses first patients in ACCESS clinical study 
